Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


06.03.2017

2 BMC Cancer
1 Breast Cancer
1 Breast Cancer Res
10 Breast Cancer Res Treat
5 Breast J
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
5 Cancer Res
2 Clin Breast Cancer
1 Clin Cancer Res
1 CMAJ
2 Eur J Cancer
1 Eur J Surg Oncol
1 Gene
3 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 JAMA
4 Lancet Oncol
1 Nat Rev Clin Oncol
1 NPJ Breast Cancer
10 PLoS One
4 Proc Natl Acad Sci U S A
3 Radiology
2 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. MORRIS M, Woods LM, Bhaskaran K, Rachet B, et al
    Do pre-diagnosis primary care consultation patterns explain deprivation-specific differences in net survival among women with breast cancer? An examination of individually-linked data from the UK West Midlands cancer registry, national screening progr
    BMC Cancer. 2017;17:155.
    PubMed     Text format     Abstract available

  2. INARI H, Suganuma N, Kawachi K, Yoshida T, et al
    Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    BMC Cancer. 2017;17:160.
    PubMed     Text format     Abstract available


    Breast Cancer

  3. KOGA C, Akiyoshi S, Ishida M, Nakamura Y, et al
    Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
    Breast Cancer. 2017 Feb 27. doi: 10.1007/s12282-017-0764.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  4. BAILUR JK, Pawelec G, Hatse S, Brouwers B, et al
    Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty.
    Breast Cancer Res. 2017;19:20.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  5. CHAKRABORTY A, Hatzis C, DiGiovanna MP
    Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
    Breast Cancer Res Treat. 2017 Feb 24. doi: 10.1007/s10549-017-4169.
    PubMed     Text format     Abstract available

  6. IGNATOV T, Eggemann H, Burger E, Costa SD, et al
    Management of small T1a/b breast cancer by tumor subtype.
    Breast Cancer Res Treat. 2017 Feb 23. doi: 10.1007/s10549-017-4168.
    PubMed     Text format     Abstract available

  7. YEONG J, Thike AA, Lim JC, Lee B, et al
    Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Feb 23. doi: 10.1007/s10549-017-4161.
    PubMed     Text format     Abstract available

  8. PARK HS, Sohn J, Kim SI, Park S, et al
    Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4175.
    PubMed     Text format     Abstract available

  9. RAPHAEL J, Paramsothy T, Li N, Lee J, et al
    A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4167.
    PubMed     Text format     Abstract available

  10. ROBERTS MC, Miller DP, Shak S, Petkov VI, et al
    Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4162.
    PubMed     Text format     Abstract available

  11. ORUCEVIC A, Bell JL, McNabb AP, Heidel RE, et al
    Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4170.
    PubMed     Text format     Abstract available

  12. SALGADO TM, Davis EJ, Farris KB, Fawaz S, et al
    Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
    Breast Cancer Res Treat. 2017 Mar 1. doi: 10.1007/s10549-017-4177.
    PubMed     Text format     Abstract available

  13. MATSUDA N, Lim B, Wang Y, Krishnamurthy S, et al
    Identification of frequent somatic mutations in inflammatory breast cancer.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4165.
    PubMed     Text format     Abstract available

  14. RAUSCHER GH, Silva A, Pauls H, Frasor J, et al
    Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities.
    Breast Cancer Res Treat. 2017 Mar 1. doi: 10.1007/s10549-017-4166.
    PubMed     Text format     Abstract available


    Breast J

  15. JINIH M, Relihan N, Corrigan MA, O'Reilly S, et al
    Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
    Breast J. 2017 Mar 2. doi: 10.1111/tbj.12783.
    PubMed     Text format     Abstract available

  16. DE FELICE F, Ranalli T, Musio D, Lisi R, et al
    Relation between Hypofractionated Radiotherapy, Toxicity and Outcome in Early Breast Cancer.
    Breast J. 2017 Mar 2. doi: 10.1111/tbj.12792.
    PubMed     Text format     Abstract available

  17. ALTUNDAG K
    Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer.
    Breast J. 2017 Mar 1. doi: 10.1111/tbj.12782.
    PubMed     Text format    

  18. PETTIFORD J, Felts S, Wischkaemper E, Miller D, et al
    A Bio-Psychosocial Intervention Program for Improving Quality of Life in Breast Cancer Survivors - Final Outcome of a Prospective Randomized Trial.
    Breast J. 2017 Feb 24. doi: 10.1111/tbj.12786.
    PubMed     Text format     Abstract available

  19. IQBAL J, Ginsburg O, Fischer HD, Austin PC, et al
    A Population-Based Cross-Sectional Study Comparing Breast Cancer Stage at Diagnosis between Immigrant and Canadian-Born Women in Ontario.
    Breast J. 2017 Mar 2. doi: 10.1111/tbj.12785.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  20. WANG Z, Chen J, Zhong MZ, Huang J, et al
    Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
    Cancer Chemother Pharmacol. 2017 Feb 27. doi: 10.1007/s00280-017-3248.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  21. THORVALDSDOTTIR B, Aradottir M, Stefansson OA, Bodvarsdottir SK, et al
    Telomere length is predictive of breast cancer risk in BRCA2 mutation carriers.
    Cancer Epidemiol Biomarkers Prev. 2017 Feb 24. pii: cebp.0946.2016.
    PubMed     Text format     Abstract available


    Cancer Res

  22. CEJALVO JM, Martinez de Duenas E, Galvan P, Garcia-Recio S, et al
    Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer.
    Cancer Res. 2017 Mar 1. pii: canres.2717.2016.
    PubMed     Text format     Abstract available

  23. ANJANAPPA M, Cardoso AA, Cheng L, Mohamad S, et al
    Individualized breast cancer characterization through single cell analysis of tumor and adjacent-normal cells.
    Cancer Res. 2017 Mar 1. pii: canres.3308.2016.
    PubMed     Text format     Abstract available

  24. KA NL, Na TY, Na H, Lee MH, et al
    NR1D1 recruitment to sites of DNA damage inhibits repair and is associated with chemosensitivity of breast cancer.
    Cancer Res. 2017 Mar 1. pii: canres.2099.2016.
    PubMed     Text format     Abstract available

  25. JANSEN VM, Bhola NE, Bauer JA, Formisano L, et al
    Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer.
    Cancer Res. 2017 Mar 1. pii: canres.2653.2016.
    PubMed     Text format     Abstract available

  26. HARRIS HR, Willett WC, Vaidya RL, Michels KB, et al
    An Adolescent and Early Adulthood Dietary Pattern Associated with Inflammation and the Incidence of Breast Cancer.
    Cancer Res. 2017;77:1179-1187.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  27. LEFEUVRE D, Le Bihan-Benjamin C, Pauporte I, Medioni J, et al
    French Medico-Administrative Data to Identify the Care Pathways of Women With Breast Cancer.
    Clin Breast Cancer. 2017 Jan 27. pii: S1526-8209(16)30321.
    PubMed     Text format     Abstract available

  28. DE BOER MC, Worner EA, Verlaan D, van Leeuwen PA, et al
    The Mechanisms and Effects of Physical Activity on Breast Cancer.
    Clin Breast Cancer. 2017 Jan 24. pii: S1526-8209(16)30422.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  29. HUSING A, Fortner RT, Kuhn T, Overvad K, et al
    Added value of serum hormone measurements in risk prediction models for breast cancer for women not using exogenous hormones: Results from the EPIC cohort.
    Clin Cancer Res. 2017 Feb 28. pii: clincanres.3011.2016.
    PubMed     Text format     Abstract available


    CMAJ

  30. HAMER J, Warner E
    Lifestyle modifications for patients with breast cancer to improve prognosis and optimize overall health.
    CMAJ. 2017;189:E268-E274.
    PubMed     Text format    


    Eur J Cancer

  31. VAN KAMPEN RJ, Ramaekers BL, Lobbezoo DJ, de Boer M, et al
    Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
    Eur J Cancer. 2017 Feb 25. pii: S0959-8049(17)30088.
    PubMed     Text format     Abstract available

  32. YOUSSEF MM, Cameron D, Olsen S, Ferguson D, et al
    Does axillary lymph node dissection impact survival in patients with breast cancer and isolated tumour cells or micrometastasis in sentinel node?
    Eur J Cancer. 2017;75:167-168.
    PubMed     Text format    


    Eur J Surg Oncol

  33. MORGAN JL, Walters SJ, Collins K, Robinson TG, et al
    What influences healthcare professionals' treatment preferences for older women with operable breast cancer? An application of the discrete choice experiment.
    Eur J Surg Oncol. 2017 Feb 2. pii: S0748-7983(17)30107.
    PubMed     Text format     Abstract available


    Gene

  34. SHUI Y, Yu X, Duan R, Bao Q, et al
    miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Delta-like 1 in breast carcinoma.
    Gene. 2017;609:80-87.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  35. JETHWA KR, Kahila MM, Hunt KN, Brown LC, et al
    Delineation of Internal Mammary Nodal Target Volumes in Breast Cancer Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2017;97:762-769.
    PubMed     Text format     Abstract available

  36. NICHOLS E, Kesmodel SB, Bellavance E, Drogula C, et al
    Preoperative Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Preliminary Results of a Prospective, Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2017;97:747-753.
    PubMed     Text format     Abstract available

  37. STICK LB, Yu J, Maraldo MV, Aznar MC, et al
    Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2017;97:754-761.
    PubMed     Text format     Abstract available


    J Clin Oncol

  38. HUMMEL SB, van Lankveld JJ, Oldenburg HS, Hahn DE, et al
    Efficacy of Internet-Based Cognitive Behavioral Therapy in Improving Sexual Functioning of Breast Cancer Survivors: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2017 Feb 27:JCO2016696021. doi: 10.1200/JCO.2016.69.6021.
    PubMed     Text format     Abstract available


    JAMA

  39. ALLEN D
    Moving the Needle on Recovery From Breast Cancer: The Healing Role of Postmastectomy Tattoos.
    JAMA. 2017;317:672-674.
    PubMed     Text format    


    Lancet Oncol

  40. BROWER V
    Scalp cooling and hair loss during breast cancer chemotherapy.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30158.
    PubMed     Text format    

  41. MATHEW A, Brufsky A
    Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30150.
    PubMed     Text format    

  42. MAYOR S
    Service review: improving breast cancer care in Tanzania.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30160.
    PubMed     Text format    

  43. LLOMBART-CUSSAC A, Cortes J, Pare L, Galvan P, et al
    HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30021.
    PubMed     Text format     Abstract available


    Nat Rev Clin Oncol

  44. HUTCHINSON L
    Breast cancer: Utidelone: burden relief in pretreated women.
    Nat Rev Clin Oncol. 2017 Mar 2. doi: 10.1038/nrclinonc.2017.
    PubMed     Text format    


    NPJ Breast Cancer

  45. QIU WG, Polotskaia A, Xiao G, Di L, et al
    Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.
    NPJ Breast Cancer. 2017;3.
    PubMed     Text format     Abstract available


    PLoS One

  46. KAN-DAPAAH K, Rahbar N, Soboyejo W
    Polymeric composite devices for localized treatment of early-stage breast cancer.
    PLoS One. 2017;12:e0172542.
    PubMed     Text format     Abstract available

  47. CHUNG IY, Lee JW, Lee JS, Park YR, et al
    Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer.
    PLoS One. 2017;12:e0170311.
    PubMed     Text format     Abstract available

  48. ISLAM S, Dasgupta H, Roychowdhury A, Bhattacharya R, et al
    Study of association and molecular analysis of human papillomavirus in breast cancer of Indian patients: Clinical and prognostic implication.
    PLoS One. 2017;12:e0172760.
    PubMed     Text format     Abstract available

  49. SIMON M, Mesmar F, Helguero L, Williams C, et al
    Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
    PLoS One. 2017;12:e0172832.
    PubMed     Text format     Abstract available

  50. PAN Y, Yuan Y, Liu G, Wei Y, et al
    P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
    PLoS One. 2017;12:e0172324.
    PubMed     Text format     Abstract available

  51. CURRY A, Khatri I, Kos O, Zhu F, et al
    Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model.
    PLoS One. 2017;12:e0171586.
    PubMed     Text format     Abstract available

  52. LEE J, Kim HH, Ro SM, Yang JH, et al
    Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
    PLoS One. 2017;12:e0171605.
    PubMed     Text format     Abstract available

  53. CLARKE CS, Hunter RM, Shemilt I, Serra-Sastre V, et al
    Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.
    PLoS One. 2017;12:e0172731.
    PubMed     Text format     Abstract available

  54. GSCHWANTLER-KAULICH D, Tan YY, Fuchs EM, Hudelist G, et al
    PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.
    PLoS One. 2017;12:e0172911.
    PubMed     Text format     Abstract available

  55. KIM MH, Lee KY, Park S, Kim SI, et al
    Effects of systemic lidocaine versus magnesium administration on postoperative functional recovery and chronic pain in patients undergoing breast cancer surgery: A prospective, randomized, double-blind, comparative clinical trial.
    PLoS One. 2017;12:e0173026.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A


  56. Correction for Gasparini et al., Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.
    Proc Natl Acad Sci U S A. 2017 Feb 27. pii: 201700727.
    PubMed     Text format    


  57. Correction for Tung et al., beta-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
    Proc Natl Acad Sci U S A. 2017 Feb 27. pii: 201702117.
    PubMed     Text format    

  58. TAVERA-MENDOZA LE, Westerling T, Libby E, Marusyk A, et al
    Vitamin D receptor regulates autophagy in the normal mammary gland and in luminal breast cancer cells.
    Proc Natl Acad Sci U S A. 2017 Feb 27. pii: 201615015.
    PubMed     Text format     Abstract available

  59. CHEN L, Jenjaroenpun P, Pillai AM, Ivshina AV, et al
    Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification.
    Proc Natl Acad Sci U S A. 2017 Mar 1. pii: 201701512.
    PubMed     Text format     Abstract available


    Radiology

  60. KIM JJ, Kim JY, Kang HJ, Shin JK, et al
    Computer-aided Diagnosis-generated Kinetic Features of Breast Cancer at Preoperative MR Imaging: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer.
    Radiology. 2017 Mar 2:162079. doi: 10.1148/radiol.2017162079.
    PubMed     Text format     Abstract available

  61. D'ORSI CJ, Sickles EA
    2017 Breast Cancer Surveillance Consortium Reports on Interpretive Performance at Screening and Diagnostic Mammography: Welcome New Data, But Not as Benchmarks for Practice.
    Radiology. 2017 Feb 28. doi: 10.1148/radiol.2017170181.
    PubMed     Text format    

  62. SPRAGUE BL, Arao RF, Miglioretti DL, Henderson LM, et al
    National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from the Breast Cancer Surveillance Consortium.
    Radiology. 2017 Feb 28:161519. doi: 10.1148/radiol.2017161519.
    PubMed     Text format     Abstract available


    Radiother Oncol

  63. YOON HI, Yoon J, Chung Y, Nam CM, et al
    Individual case review in a phase 3 randomized trial to investigate the role of internal mammary lymph node irradiation for breast cancer: Korean Radiation Oncology Group 08-06 study.
    Radiother Oncol. 2017 Feb 21. pii: S0167-8140(17)30045.
    PubMed     Text format     Abstract available

  64. PRADES J, Algara M, Espinas JA, Farrus B, et al
    Understanding variations in the use of hypofractionated radiotherapy and its specific indications for breast cancer: A mixed-methods study.
    Radiother Oncol. 2017 Feb 21. pii: S0167-8140(17)30039.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: